Iovance Biotherapeutics surges as institutional investors shift Qualcomm and Atkore holdings

Various companies and institutional investors have shown significant movement in their stock holdings and market performance.

Iovance Biotherapeutics, Inc. has experienced a major rally, with its stock rising over 130% in 2026. Following record revenue for Amtagvi and improved gross margins in Q2 2026, the stock reached a 52-week high, closing at $6.98. Despite the bullish trend, technical indicators such as the RSI suggest overbought conditions.

In terms of institutional shifts, Crossmark Global Holdings Inc. reduced its position in Qualcomm Incorporated by 17.8% during the second quarter, leaving it with 375,705 shares valued at approximately $69.43 million. Conversely, other firms like World Investment Advisors and MUFG Securities EMEA plc increased their stakes in Qualcomm.

Bank of America Corp DE also adjusted its portfolio by increasing its holdings in Atkore Inc. by 10.1% during the first quarter, bringing its total ownership to 462,278 shares valued at roughly $27.23 million.